This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knoop, A. S. Articles by Rose, C. Search for Related Content PubMed PubMed Citation Articles by Knoop, A. S. Articles by Rose, C. Social Bookmarking                            What's this?

Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients

From the Oncological Research Center, Odense University Hospital, Odense, and Roskilde County Hospital, Roskilde, Denmark; and Gray Laboratory Cancer Research Trust, Northwood, United Kingdom.

Address reprint requests to Ann S. Knoop, MD, PhD, Oncological Research Center, Odense University Hospital, DK-5000 Odense C, Denmark; email: knoop{at}dadlnet.dk

PURPOSE: Few studies have examined the possible importance of biologic prognostic factors in breast cancer connected with differentiation and growth in predicting response to a specific adjuvant treatment. HER2, epidermal growth factor receptor (EGFR), and p53 have all been suggested as possible markers of tamoxifen resistance. The aim of this study was to investigate interactions between adjuvant treatment with tamoxifen and the content of EGFR, HER2, and p53 in steroid receptor–positive patients.

PATIENTS AND METHODS: A total of 1,716 high-risk postmenopausal breast cancer patients were randomly assigned to treatment with tamoxifen (868 women) or to observation (848 women) in a prospective trial (Danish Breast Cancer Cooperative Group’s 77c protocol). The content of the steroid receptors and expression of p53, EGFR, and HER2 were determined by immunohistochemical analysis of paraffin-embedded tissue. The length of follow-up was 10 years. The end point for this analysis was disease-free survival.

RESULTS: Multivariate analysis demonstrated no increased risk of recurrence after treatment with tamoxifen for HER2-, EGFR-, and p53-positive, high-risk, steroid receptor–positive patients. Patients with steroid receptor–positive tumors and positive immunohistochemical staining for HER2, EGFR or p53 benefited from treatment with tamoxifen for 1 year, although the latter variable contained independent prognostic information by itself.

CONCLUSION: With the statistical power of the present randomized study, we did not find support for the hypothesis that HER2/EGFR or p53 status predicts benefit from tamoxifen treatment in estrogen receptor–positive patients with early-stage breast cancer. Thus, neither HER2, EGFR, nor p53 overexpression/accumulation should be used as a contraindication for giving tamoxifen.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. U. Buzdar Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer Ann. Onc., June 1, 2009; 20(6): 993 - 999. [Abstract] [Full Text] [PDF]

				V. Vinh-Hung, H. M. Verkooijen, G. Fioretta, I. Neyroud-Caspar, E. Rapiti, G. Vlastos, C. Deglise, M. Usel, J.-M. Lutz, and C. Bouchardy Lymph Node Ratio as an Alternative to pN Staging in Node-Positive Breast Cancer J. Clin. Oncol., March 1, 2009; 27(7): 1062 - 1068. [Abstract] [Full Text] [PDF]

				M. Colleoni, G. Viale, D. Zahrieh, L. Bottiglieri, R. D. Gelber, P. Veronesi, A. Balduzzi, R. Torrisi, A. Luini, M. Intra, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann. Onc., March 1, 2008; 19(3): 465 - 472. [Abstract] [Full Text] [PDF]

				K. I. Pritchard, H. Messersmith, L. Elavathil, M. Trudeau, F. O'Malley, and B. Dhesy-Thind HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy J. Clin. Oncol., February 10, 2008; 26(5): 736 - 744. [Abstract] [Full Text] [PDF]

				Y. Moon, G. Park, K. Han, C.-S. Kang, and W. Lee Mouse Spleen Tissue as a Staining Intensity Reference for Immunohistochemistry Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 215 - 220. [Abstract] [Full Text] [PDF]

				W. A. Woodward, V. Vinh-Hung, N. T. Ueno, Y. C. Cheng, M. Royce, P. Tai, G. Vlastos, A. M. Wallace, G. N. Hortobagyi, and Y. Nieto Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2910 - 2916. [Abstract] [Full Text] [PDF]

				N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747. [Abstract] [Full Text] [PDF]

				L. Ryden, K. Jirstrom, P.-O. Bendahl, M. Ferno, B. Nordenskjold, O. Stal, S. Thorstenson, P.-E. Jonsson, and G. Landberg Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4695 - 4704. [Abstract] [Full Text] [PDF]

				M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, et al. A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4741 - 4748. [Abstract] [Full Text] [PDF]

				S. Tovey, B. Dunne, C. J. Witton, A. Forsyth, T. G. Cooke, and J. M.S. Bartlett Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? Clin. Cancer Res., July 1, 2005; 11(13): 4835 - 4842. [Abstract] [Full Text] [PDF]

				J. Andersson, L. Larsson, S. Klaar, L. Holmberg, J. Nilsson, M. Inganas, G. Carlsson, J. Ohd, C.-M. Rudenstam, B. Gustavsson, et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF Ann. Onc., May 1, 2005; 16(5): 743 - 748. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]

				S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al. Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046. [Abstract] [Full Text] [PDF]

				R. R. Love, N. B. Duc, T. C. Havighurst, S. K. Mohsin, Q. Zhang, D. L. DeMets, and D. C. Allred HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer J. Clin. Oncol., February 1, 2003; 21(3): 453 - 457. [Abstract] [Full Text] [PDF]

				C. L. Arteaga Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? Oncologist, August 15, 2002; 7(90004): 31 - 39. [Abstract] [Full Text] [PDF]